Table 1. Impact of baseline characteristics on patient prognosis (N = 203).
| Total N = 203 (%) | 5Y DRFS (%) | P-value | |
|---|---|---|---|
| Age (median) | 46.4 ± 10.2 | ||
| Range | 23.5–74.1 | 0.633 | |
| <40 YO1 | 48 (23.6) | 81.2 | |
| ≥40 YO | 155 (76.4) | 86.4 | |
| Histology | 0.507 | ||
| IDC2 | 180 (88.7) | 85.5 | |
| Other | 23 (11.3) | 82.9 | |
| Stage | <0.001 | ||
| I | 55 (27.1) | 90.9 | |
| IIA | 94 (46.3) | 91.5 | |
| IIB | 33 (16.3) | 78.8 | |
| IIIA | 13 (6.4) | 67.7 | |
| IIIB | 0 (0) | ||
| IIIC | 8 (3.9) | 25.0 | |
| Nuclear grade | 0.258 | ||
| 1 | 2 (1.0) | 50.0 | |
| 2 | 47 (23.2) | 82.8 | |
| 3 | 145 (71.4) | 86.9 | |
| Unknown | 9 (4.4) | 77.8 | |
| Histologic grade | 0.704 | ||
| 1 | 3 (1.5) | 100.0 | |
| 2 | 45 (22.2) | 84.4 | |
| 3 | 144 (70.9) | 86.0 | |
| Unknown | 11 (5.4) | 72.7 | |
| Adjuvant chemotherapy | 0.001 | ||
| CMF3 | 86 (42.4) | 90.7 | |
| FAC4 | 58 (28.6) | 86.0 | |
| AC5 | 17 (8.4) | 100.0 | |
| AC –T6 | 41 (20.2) | 65.9 | |
| Unknown | 1 (0.5) | 100.0 | |
| Adjuvant RTx5 | 0.093 | ||
| Yes | 130 (64.0) | 83.0 | |
| No | 73 (36.0) | 89.0 | |
| NFKB1 (median: 25.60) | 0.057 | ||
| Low | 101(49.9%) | 81.2 | |
| High | 102(50.1%) | 89.1 | |
| NFKB2 (median: 297.30) | 0.793 | ||
| Low | 101(49.9%) | 85.1 | |
| High | 102(50.1%) | 85.3 | |
| RELA (median: 224.85) | 0.061 | ||
| Low | 101(49.9%) | 90.0 | |
| High | 102(50.1%) | 80.4 | |
| RELB (median: 61.25) | 0.567 | ||
| Low | 101(49.9%) | 86.1 | |
| High | 102(50.1%) | 84.3 | |
| REL (median: 65.48) | 0.411 | ||
| Low | 101(49.9%) | 82.2 | |
| High | 102(50.1%) | 88.2 | |
| TP53 (median: 221.06) | 0.957 | ||
| Low | 101(49.9%) | 85.3 | |
| High | 102(50.1%) | 85.1 | |
| FOXC1 (median: 126.94) | 0.678 | ||
| Low | 101(49.9%) | 87.1 | |
| High | 102(50.1%) | 83.3 | |
| TBP (median: 92.68) | 0.307 | ||
| Low | 101(49.9%) | 87.1 | |
| High | 102(50.1%) | 83.3 | |
| SP1 (median: 100.01) | 0.024 | ||
| Low | 101(49.9%) | 90.1 | |
| High | 102(50.1%) | 80.3 | |
| STAT3 (median:1599.68) | 0.732 | ||
| Low | 101(49.9%) | 86.1 | |
| High | 102(50.1%) | 84.3 | |
| IRF1 (median: 192.75) | 0.758 | ||
| Low | 101(49.9%) | 86.1 | |
| High | 102(50.1%) | 84.3 |
1Years old, 2Invasive ductal carcinoma, 3Cyclophospamide/Methotrexate/Fluorouracil, 4Fluorouracil/Adriamycin/Cyclophosphamide, 5Adriamycin/Cyclophosphamide, 6Taxane, 7Radiotherapy.